Arcutis Biotherapeutics Inc
(NAS:ARQT)
$
10.25
-0.59 (-5.44%)
Market Cap: 1.20 Bil
Enterprise Value: 1.15 Bil
PE Ratio: 0
PB Ratio: 7.65
GF Score: 29/100 Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 06:55PM GMT
Release Date Price:
$8.19
(+5.13%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. All right. Welcome, everyone. This is the fireside chat with our Arcutis Biotherapeutics. My name is Vikram Purohit. I'm one of the biotech analysts with the research team. Thanks for joining us.
Before we get started, I need to read a brief disclosure statement for important disclosures. Please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
With that, happy to have with me Frank and Patrick from Arcutis. Thanks for joining us.
Todd Franklin Watanabe
Arcutis Biotherapeutics, Inc. - President, CEO & Director
Thanks.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Quite a lot to cover in roughly 30 minutes, but Frank, I wanted to turn it over to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot